Myelodysplastic Syndromes
"Myelodysplastic Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Descriptor ID |
D009190
|
MeSH Number(s) |
C15.378.190.625
|
Concept/Terms |
Myelodysplastic Syndromes- Myelodysplastic Syndromes
- Myelodysplastic Syndrome
- Syndrome, Myelodysplastic
- Syndromes, Myelodysplastic
- Dysmyelopoietic Syndromes
- Dysmyelopoietic Syndrome
- Syndrome, Dysmyelopoietic
- Syndromes, Dysmyelopoietic
Hematopoetic Myelodysplasia- Hematopoetic Myelodysplasia
- Hematopoetic Myelodysplasias
- Myelodysplasia, Hematopoetic
- Myelodysplasias, Hematopoetic
|
Below are MeSH descriptors whose meaning is more general than "Myelodysplastic Syndromes".
Below are MeSH descriptors whose meaning is more specific than "Myelodysplastic Syndromes".
This graph shows the total number of publications written about "Myelodysplastic Syndromes" by people in this website by year, and whether "Myelodysplastic Syndromes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 2 | 1 | 3 |
1996 | 8 | 0 | 8 |
1997 | 5 | 2 | 7 |
1998 | 1 | 1 | 2 |
1999 | 1 | 2 | 3 |
2000 | 5 | 1 | 6 |
2001 | 2 | 0 | 2 |
2002 | 9 | 1 | 10 |
2003 | 3 | 2 | 5 |
2004 | 2 | 1 | 3 |
2005 | 5 | 1 | 6 |
2006 | 3 | 0 | 3 |
2007 | 4 | 2 | 6 |
2008 | 3 | 1 | 4 |
2009 | 10 | 4 | 14 |
2010 | 4 | 1 | 5 |
2011 | 6 | 0 | 6 |
2012 | 7 | 0 | 7 |
2013 | 8 | 1 | 9 |
2014 | 9 | 1 | 10 |
2015 | 10 | 0 | 10 |
2016 | 9 | 4 | 13 |
2017 | 12 | 2 | 14 |
2018 | 7 | 1 | 8 |
2019 | 7 | 0 | 7 |
2020 | 8 | 1 | 9 |
2021 | 3 | 1 | 4 |
2022 | 10 | 0 | 10 |
2023 | 14 | 0 | 14 |
2024 | 5 | 2 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myelodysplastic Syndromes" by people in Profiles.
-
STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia. Haematologica. 2024 Jun 01; 109(6):1825-1835.
-
Malignant progression of preleukemic disorders. Blood. 2024 May 30; 143(22):2245-2255.
-
Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome. Curr Treat Options Oncol. 2024 Jun; 25(6):752-768.
-
Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene-Environment Interactions. Cancer Discov. 2024 Mar 01; 14(3):396-405.
-
Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML. Blood Adv. 2024 02 13; 8(3):553-561.
-
Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders. Best Pract Res Clin Haematol. 2024 Mar; 37(1):101537.
-
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan; 11(1):e15-e26.
-
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). Br J Haematol. 2024 Apr; 204(4):1243-1248.
-
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Ann Hematol. 2024 Jan; 103(1):105-116.
-
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023 Dec; 10(12):e994-e1005.